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Neointimal hyperplasia is principally responsible for in-stent restenosis and remains an 
important clinical problem in the treatment of vascular occlusions. Stent material and surface 
properties are key determinants in the formation of acute thrombus and in-stent restenosis [1]. 
Commonly used bare metal stents offer excellent mechanical stability, but often increase the 
incidence of inflammation, thrombosis, fibromuscular proliferation and formation of 
restenosis [1,2]. Recently, drug-eluting stents (DES), which have synthetic polymer coatings 
that act as drug reservoirs and elute drugs over a period of several weeks or months, have 
emerged [3–6]. These DES can provide luminal scaffolding that virtually eliminates recoil 
and remodeling of the treated vessel. Additionally, the polymer coatings contain drugs that 
inhibit thrombus formation, inflammation or vascular smooth muscle cell (VSMC) 
proliferation [5]. After the drug elutes from the polymer coatings, the residual synthetic 
polymer coatings remain in place. Eventually, the permanent presence of the nonresorbable 
polymer may lead to complications, such as an exaggerated inflammatory response and 
neointima formation, at the implant site [7,8]. It is, therefore, desirable to develop DES not 
only with a biocompatible and biodegradable coating to prevent these unfavorable effects, but 
also loaded with effective drugs that either promote re-endothelization or suppress 
inflammation and VSMC proliferation [9,10]. 
Our attention has been paid to (–)-epigallocatechin-3-O-gallate (EGCG), a main 
polyphenolic component of green tea, since it has a wide range of pharmacological activities, 
including antioxidant, anti-proliferative, anti-inflammatory, anti-atherogenic and anti-
thrombotic effects [11–14]. Biodegradable copolymers, such as poly(lactide-co-ε-
caprolactone, PLCL) and poly(glycolide-co-ε-caprolactone), have been shown to possess 
vascular tissue compatibility, flexible and rubber-like elasticity and proper degradability 
[15,16]. Our earlier study has already shown that EGCG inhibits the proliferation and 
migration of serum-stimulated VSMCs in vitro and induces cell cycle arrest via nuclear 
factor-κB down-modulation [17]. In this study, we hypothesized that loading EGCG in 
coating of DES can make the in-stent restenosis, thrombosis and inflammation decrease 
significantly by inhibiting the migration and invasion of VSMCs as well as the adhesion and 
activation of platelets. EGCG releasing PLCL films were prepared and their various in vitro 
physicochemical characteristics, drug release profiles and in vitro blood compatibility are 
investigated.  
 
2. Materials and methods 
 
2.1. Preparation of EGCG-releasing PLCL 
 
PLCL [75:25 (mol/mol), molecular weight (MW) 130 ~ 150 kDa] resin used in this study 
was kindly provided by BMG Inc. (Kyoto, Japan). EGCG-releasing PLCL (E-PLCL) was 
prepared by solvent casting. PLCL resins were dissolved in acetone at 60°C and blended with 
5 wt% EGCG (MW 458.4, Teavigo™, DSM Nutritional Products Ltd., Basel, Switzerland). 
The mixtures were cast on glass Petri dishes and allowed to dry solvent slowly at room 
temperature overnight. Next the cast films were put under a vacuum to evaporate residual 
solvent for 2 days, resulting in smooth and non-porous films. PLCL and E-PLCL films were 
cut into a disc of 10 mm in diameter and 100 µm in thickness. These discs weighed about 10 
mg, unless otherwise specified. Thus, approximately 500 µg (≈ 1.1 mmol) EGCG was loaded 
in one E-PLCL disc. In order to examine VSMC behaviors onto E-PLCL films and their anti-
thrombotic activity, the films were sterilized with ethylene oxide gas and adhered onto the 
bottom of well plates by using sterile vacuum grease. 
 2.2. Physicochemical characterization 
 
2.2.1. Scanning electron microscopy (SEM) 
The surface morphologies of PLCL and E-PLCL films were examined under a field 
emission scanning microscope (Hitachi S−800, Tokyo, Japan). The films were mounted and 
sputter-coated with gold using an ion coater and then observed at an accelerating voltage of 
20 kV. 
 
2.2.2. Differential scanning calorimetry (DSC) 
The endothermic scans of PLCL and E-PLCL films were obtained by DSC, using a 
scanning rate of 10°C/min from 25 to 300°C. A DSC−3100SA (MAC Science Co., Ltd., 
Yokohama, Japan) system connected to a low-temperature refrigerator system (Intracooler II) 
was used. Liquid nitrogen was used to purge the film head and glove box. The instrument 
was calibrated using aluminum at the same scanning rate as the films (≈ 2 mg). All DSC runs 
were repeated in triplicate. For comparison, the endothermic profile of free EGCG was also 
scanned. 
 
2.2.3. Attenuated total reflectance/Fourier transformed-infrared (ATR/FT-IR) spectroscopy 
The infrared spectra of PLCL and E-PLCL films were obtained between 4,150 and 650 
cm-1 using an ATR/FT-IR spectrophotometer (Spectrum one FT-IR Spectrometer, 
Perkin−Elmer, Boston, MA). 
 
2.2.4. Water contact angle 
To compare the hydrophilicity of E-PLCL with that of PLCL, water contact angles were 
examined by the sessile droplet method. The contact angles of water onto PLCL and E-PLCL 
films were measured at room temperature using a contact angle meter (Model CA−X, Kyowa 
Interface Science Co., Ltd., Saitama, Japan) equipped with a special optical system and a 
charge-coupled device camera. 
 
2.3. In vitro release profile of EGCG from E-PLCL 
 
E-PLCL films were adhered to the bottom of a glass vial by using sterile vacuum grease 
and then incubated in phosphate-buffered saline (PBS, pH 7.4) at 37°C for up to 34 days. At 
the end of each predetermined incubation period, the absorbance at 275 nm was quantified 
using a UV spectrophotometer (U−2800A, Hitachi, Tokyo, Japan). The concentration (µM) 
of EGCG released from E-PLCL was calculated from the standard calibration curve of 
EGCG solution. 
 
2.4. In vitro degradation 
 
MW change (%) and cumulative weight loss (%) were used as indices of PLCL 
degradation. PLCL and E-PLCL films were cut into 15 mm × 5 mm (100 µm in thickness) 
and weighed respectively using an analytical balance. Weighed films were immersed in 3 ml 
of PBS and incubated in a bioshaker (BR−4OLF, Taitec, Saitama, Japan) at 37°C with 
shaking at 60 rpm for up to 8 weeks. The PBS was refreshed every week. At determined time 
intervals, films were retrieved, washed with distilled water and dried in a vacuum desiccator 
for 24 h at room temperature. Immediately after vacuum-drying, the MW of PLCL was 
measured by gel permeation chromatograph system (GPC, HLC−8020, Toyo soda, Tokyo, 
Japan) with a refractive detector and TSK gel G5000HXL and G3000HXL columns. 
Polystyrene standards were used for calibrating MW. The mass loss of PLCL and E-PLCL 
films was determined as percentage (%) of the dry weight of each film at each time divided 
by its initial dry weight. 
 
2.5. VSMC culture 
 
VSMCs were isolated by limited enzymatic digestion from the tunica media of thoracic 
aorta of male adult (10 week old) Sprague Dawley rats (280 ~ 300 g in weight, Shimizu 
Laboratory Supplies, Kyoto, Japan) as previously reported [18]. The primarily cultured 
VSMCs were cultured in a complete Dulbecco’s modified Eagle’s medium (DMEM, 
Sigma−Aldrich Co., St. Louis, MO), supplemented with 10% fetal bovine serum (FBS, 
Sigma−Aldrich) and 1% antibiotic antimycotic solution (including 10,000 units penicillin, 10 
mg streptomycin and 25 µg amphotericin B per ml, Sigma−Aldrich) at 37°C and 5% CO2 in a 
humid environment. Studies were performed with the cells between the third to seventh 
passage. 
 
2.6. VSMC migration and invasion assays 
 
Using a method similar to that previously described [19], in vitro migration assay was 
performed. Briefly, VSMCs (2 × 104 cells/ml) were seeded into 48-well plates, where PLCL 
films had been placed on the bottom of wells, and then grown to confluence. Monolayers 
were scraped (denuded) using a 1 ml plastic micropipette tip and replaced with conditioned 
media obtained by incubating either PLCL or E-PLCL in complete DMEM for 72 h, followed 
by incubation in a CO2 incubator. The cells, that migrated toward denuded space for 72 h, 
were visualized by immuno-cytochemical analysis using mouse monoclonal anti-α-smooth 
muscle actin (SMA) antibody (Clone 1A4, Sigma−Aldrich) conjugated with FITC isomer I 
and propidium iodide (5 µM, Sigma−Aldrich), counterstaining agent for cell nuclei. These 
cultures were then examined under a fluorescence microscope (Biozero−8000, Keyence, 
Osaka, Japan) using a modified method as previously described [20]. The average area 
covered by migrated cells was calculated by using an image processing software (BZ 
analyzer Ver. 2.5, Keyence). 
An invasion assay was performed in vitro using a modified Boyden chamber assay [21]. 
Briefly, the membrane (8.0 µm pore size) of transwell inserts (Nunc, Rochester, NY) was 
coated with 20 µl of matrigel solution (1 mg/ml) in DMEM for 12 h at 4°C and then rinsed 
twice with PBS. VSMCs were seeded in the inner chamber of transwell at 5 × 104 cells/well 
and given 300 µl of conditioned media obtained by incubating either PLCL or E-PLCL for 72 
h in a serum-free DMEM. The lower chamber was filled with 500 µl of a complete DMEM 
and incubated for 72 h at 37°C in a CO2 incubator. After incubation, all the non-migrant cells 
were removed from the upper face of the transwell membrane with a cotton swab and migrant 
cells were stained with 0.5% toluidene blue solution. The number of cells that had invaded 
through the membrane was counted in six randomly chosen fields of each transwell by using 
an inverted microscope (IX70, Olympus Optical Co., Osaka, Japan).  
 
2.7. Platelet adhesion and activation assays 
 
Platelet adhesion and activation were employed as indices of the anti-thrombotic effects 
of E-PLCL. Human whole blood was collected into a polypropylene syringe containing acid 
citrate dextrose A (an anticoagulant solution, 1/6 volume of blood). The upper platelet-rich 
plasma (PRP) layer was obtained by centrifuging whole blood at 1000 rpm for 10 min. Both 
films were immersed in PBS for 30 min to equilibrate the surface and then incubated with 
PRP for 2 h at 37°C. The films were washed with PBS three times to remove non-adherent 
platelets and soaked in 2.5% glutaraldehyde (Sigma−Aldrich) for 2 h to fix adhered platelets. 
After washing with PBS, the films were dehydrated in a graduated ethanol solution for 5 min 
each (50 ~ 100%) and dried in a desiccator at room temperature. The platelet-adhered 
surfaces were sputter-coated with gold using an ion coater and then examined by SEM 
(Hitachi S−800) at an accelerating voltage of 10 kV. The number of adhered platelets was 
counted from SEM micrographs with higher magnification (×1000). 
Platelet activation was investigated by determining soluble P-selectin (CD62) with an 
enzyme immunoassay kit (Takara Bio Inc., Tokyo, Japan). According to the manufacturer’s 
instructions, PRP, following incubation with either PLCL or E-PLCL film, was added to a 
96-well plate coated with mouse monoclonal anti-CD62 antibody and then incubated for 2 h 
at room temperature. Standard P-selectin (0, 10, 20, 40, 80, 160 and 320 ng/ml) was also 
reacted. To block nonspecific antibody binding, the wells were blocked with 1% bovine 
serum albumin (Sigma−Aldrich) in PBS for 30 min at room temperature. After rinsed three 
times with PBS, the wells were incubated with peroxidase-conjugated anti-mouse secondary 
antibody for 1 h at room temperature. Hydrogen peroxide/tetramethylbenzidine substrate 
agent was added to the wells for color development and further incubated for 15 min. 
Afterwards, the enzyme reaction was stopped by the addition of 1N H2SO4, and absorbance 
was determined at 450 nm with a microplate reader (VersaMax™, Molecular Devices Co., 
Sunnyvale, CA). 
 
2.8. Preparation of EGCG-eluting stents and balloon-expansion test 
 Stents (17 mm in length, 1.6 mm in diameter) consisting of Co-Cr alloy were kindly 
donated by Japan Stent Technology Co. Ltd. (Okayama, Japan). PLCL and EGCG were 
dissolved in acetone to yield a solution of 0.5 wt% (0.475% and 0.025%, respectively). The 
PLCL solution containing EGCG was sprayed onto the surface of stents using an ultrasonic 
spray-coating method with stent coating system (MediCoat™ DES 1000, Sono−Tek Co. Ltd., 
Milton, NY). The mass of the coating sprayed onto the stent surface was obtained by 
weighing the stent before and after spraying. The coating weight for a stent was 
approximately 620 µg, and the resulting drug content was about 30 µg. The surface 
morphology of EGCG-eluting stents before and after balloon-expansion was examined with 
digital microscope (VHX−100, Keyence). The layer quality and structural integrity of E-
PLCL coating after balloon-expansion were examined by SEM (Shimazu SS−550). The stent 
was mounted onto an angioplasty balloon and the balloon was dilated to 3.0 mm at a pressure 
of 20 atm. 
 
2.9. Statistical analysis 
 
All variables were tested in three independent cultures for each experiment, and each 
experiment was repeated twice (n = 6). Quantitative data is expressed as mean ± standard 
deviation (SD). Statistical comparisons were carried out with a one-way analysis of variance 
(ANOVA, SAS Institute Inc., Cary, NC, USA), which was followed by the Bonferroni test 
for the multiple comparisons. A value of p < 0.05 was considered statistically significant. 
 
3. Results 
 3.1. Physicochemical characteristics of E-PLCL 
 
E-PLCL was prepared by blending PLCL with 5 wt% EGCG which induced a red-color 
because of EGCG addition. The physicochemical properties of PLCL and E-PLCL films 
were examined by SEM, DSC, FT-IR spectroscopy and water contact angle. SEM 
demonstrated that the surface morphology and roughness of E-PLCL (Fig. 1A) was almost 
similar to those of PLCL. The DSC profiles showed that the melting temperature (Tm) of 
PLCL was slightly lowered to 153.5°C from 154.2°C by EGCG impregnation (Fig. 1B). The 
conversion T of EGCG into GCG, its epimer, was near 97°C (a, the insert of Fig. 1B). The 
Tm of GCG was at 223°C (b), the crystallization T of EGCG was at 235°C (c) and the Tm of 
EGCG was at 246°C (d). This result suggests that EGCG addition might not affect the 
crystallinity of PLCL.  
FT-IR spectrum of E-PLCL was dominated by a broad noticeable band at 3,600 ~ 3,150 
cm-1, which is the characteristic peak of phenyl – OH groups abundant in EGCG (Fig. 2A, 
top). Additionally, the characteristic bands of EGCG were found at 1610 cm-1 for C = C 
alkenes and at 823 cm-1 for C – H alkenes (Fig. 1C, bottom). Strong peaks of PLCL and E-
PLCL near 1750 cm-1 were derived from the carbonyl stretching (C = O) of the PLA and PCL 
block. Furthermore, the characteristic peaks of EGCG were not shifted in E-PLCL. Therefore, 
it seemed that EGCG might be well dispersed in E-PLCL film. To compare the hydrophilicity 
of PLCL with that of E-PLCL, the water contact angles were measured using the sessile 
droplet method. The water contact angle of PLCL was 83.8±1.8° and that of E-PLCL was 
78.2±1.6°. These results showed that the hydrophilicity of PLCL was significantly (p < 0.05) 
increased, which was attributed to the presence of hydrophilic groups in EGCG.  
 
3.2. EGCG release from E-PLCL and effects of EGCG blending on PLCL degradation 
 
The EGCG release profiles were examined to determine whether EGCG could be released 
from E-PLCL in amounts necessary to generate effective concentrations that inhibit the 
behaviors of VSMCs. As shown in Fig. 2A, EGCG was released in a logarithmic manner, in 
which the release rate decreased with time. A minor burst effect of less than 6% was 
observed during the first day of release. E-PLCL sustainedly released approximately 30% of 
blended EGCG during the first 30 days. This release profile is characteristic of diffusion 
controlled systems. From the release profile, it was found that about 110 µM EGCG was 
cumulatively released from E-PLCL for 3 days. 
In vitro PLCL degradation was investigated by measuring MW change and mass loss. 
The MW of PLCL could be determined by GPC, however the MW of E-PLCL could not be 
measured due to adsorption of EGCG to the GPC columns. As shown in Fig. 2B, the MW 
was 10% of initial value after 1week and approximately 60% of the initial value after 8 weeks. 
However, the mass loss of PLCL was insignificant, during test periods (Fig. 2C). The MWs 
decreased to a larger extent than the change of mass loss, which is typical for such aliphatic 
polyesters. Aliphatic polyesters such as PGA, PLA and PCL are degraded by non-enzymatic 
random hydrolytic scission of esters linkage. The mass of E-PLCL gradually decreased until 
6 weeks, but its mass loss accelerated at 8 weeks to approximately 4% loss of the initial 
weight (Fig. 2C). These results indicate that the mass loss of E-PLCL during incubation 
might be due to the release of EGCG from PLCL matrices. The EGCG release profile closely 
matches that of E-PLCL mass loss, suggesting that the main release mechanism during the 
test period might be diffusion, rather than polymer degradation. 
 
3.3. Migration and invasion of VSMCs onto E-PLCL 
 The in vitro wound healing migration assay, created from a scrape wound in a confluent 
cell monolayer, was used to assess the effect of EGCG released from E-PLCL on VSMC 
migration. After scrape wounding, the behaviors of VSMC in the conditioned media obtained 
from either PLCL or E-PLCL were monitored. The initial denuded area onto PLCL was 1.43 
± 0.21 mm2. With conditioned media from PLCL, the first evidence of cell ingrowth did not 
appear until around 24 h. Some parts of a scrape started to recover by 48 h after denuding 
(data not shown). After 72 h the denuded space was well filled in with cells indicating that 
scrape recovery was nearly complete (Fig. 3A). Since the doubling time for VSMCs with 
FBS stimulation is about 44 h, the commencement of the recovery with conditioned media 
from PLCL at 48 h implies that the cells had extensively migrated from the edge of the scrape 
into the denuded space immediately after the onset of cell proliferation. On the contrary, the 
denuded area closure in FBS-induced VSMCs with conditioned media from E-PLCL was 
completely suppressed after 72 h (Fig. 3A). The denuded area remained unpopulated until 48 
h, even though a few cells at the edge of the scrape showed some forward movement (data 
not shown). VSMCs with conditioned media from E-PLCL showed neither migration nor 
ingrowth even after the onset of cell proliferation. The unrecovered area of scrape in VSMCs 
with conditioned media from PLCL and that from E-PLCL after 72h were 0.2±0.2 mm2 and 
1.32±0.2 mm2, respectively. While about 14% of the initially denuded area remained 
uncovered after 72 h in VSMCs with conditioned media from PLCL, the cells with 
conditioned media from E-PLCL covered only 8% of the initial area. There was significant (p 
< 0.05) difference in the uncovered area between the cells with conditioned media from 
PLCL and E-PLCL after 72 h.  
To determine whether EGCG released from E-PLCL affects VSMC invasion through 
extracellular matrices or not, a modified Boyden chamber assay was performed. Conditioned 
media from E-PLCL completely suppressed the invasion of VSMCs after 72 h despite FBS 
stimulation, whereas most of the cells with conditioned media from PLCL invaded through 
extracellular matrices in response to FBS (Fig. 3B). The number of cells that had invaded 
across the reconstituted basement membrane was 121.4 ±8.6 and 116.8±9.0 for conditioned 
media from PLCL and fresh media, respectively. However when conditioned media from E-
PLCL was used only 21.2 ±2.8 cells had invaded across the membrane. These results indicate 
that EGCG released from E-PLCL significantly (p < 0.05) inhibits VSMC invasion for at 
least 72 h. These results suggest that EGCG released from E-PLCL may be effective in 
inhibiting the migration of VSMCs across a thin layer as well as their invasion through a 
thick layer. 
 
3.4. Adhesion and activation of platelets onto E-PLCL 
 
The anti-thrombotic effects of E-PLCL were examined by assaying platelet adhesion and 
activation. Fig. 4A showed the morphologies of platelets adhered onto the surfaces of PLCL 
and E-PLCL films. The platelets adhered onto PLCL film were spread and had developed 
characteristic pseudopodia, which were typical morphologies of the activated states. Onto E-
PLCL, however, platelet adhesion and aggregation were remarkably reduced with neither 
extension of pseudopodia nor deformation. The platelets adhered onto E-PLCL film were 
generally singular with a rounded shape. This morphology is typical of inactivated states. 
Moreover, the average number of platelets adhered on the different films was counted from 
SEM images (×1000). The number of platelets adhered onto PLCL films was 49.1±10.98 
and that onto E-PLCL films was 11.1±2.91. After EGCG was incorporated into PLCL films, 
the number of adherent platelets significantly (p < 0.05) decreased. The activation of platelets 
leads to a rapid change of platelet morphology with formation of pseudopodia, spreading and 
the onset of release reaction, followed by platelet aggregation [22]. P-selectin is present on 
the surface of activated platelets or released into plasma, and thus may be used as a marker of 
platelet activation onto biomaterials [22,23]. The amount of P-selectin released by platelets 
activated by E-PLCL was 84.7 % of the amount released by platelets adherent to PLCL (p < 
0.05), suggesting that platelet activation was suppressed by EGCG when incubated in human 
plasma (Fig 4B). These results suggest that EGCG might improve the blood compatibility of 
PLCL via reducing platelet adhesion and activation. 
 
3.5. Surface morphology and structural integrity of EGCG-eluting stents 
 
Apart from pharmacokinetic requirements, polymer coatings containing a drug on 
metallic stents have to remain adherent and undamaged during stent implantation and 
expansion. For DES, surface topography is considered an important determinant of the bare 
stent performance. If the stent has webbings and bridges between the struts, the coating may 
break off from the stent when the stent is dilated by a balloon catheter. Thrombus and VSMC 
proliferation can occur at the site where the coating breaks off [22,24]. E-PLCL layers were 
able to mask impurities of bare stents and to smooth the surface, with uniform distribution 
over both exterior and interior surfaces (Fig. 5A). There were no cracks or webbings between 
struts after balloon-expansion. A smooth surface coating can significantly decrease injury to 
blood vessels. Furthermore, a smooth stent surface is believed to reduce platelet activation 
and aggregation, consequently leading to less thrombus formation and neointimal 
proliferation [22]. It was also found that the structural integrity of the stent coatings was 
maintained without delamination or destruction after 90% dilatation by an angioplasty 
balloon (Fig. 5B). This indicates that the stent coating has rubber-like elasticity and is 
sufficiently flexible to allow balloon expansion of the stent without cracking or peeling from 
the struts. A close fit of the polymer layer around the stent strut is essential for maintaining 
structural integrity of the coated stents during crimping and dilatation. Thus, it seemed that E-
PLCL coatings enable EGCG-eluting stents to withstand compressive and tensile strains 




It is likely that local delivery of anti-proliferative, anti-migratory anti-thrombotic and 
anti-inflammatory drugs can prevent stent restenosis [25,26]. The principle hereby 
investigated was the application of a polymer coating as a vehicle for drug delivery, rather 
than to study a specific stent. In the present study, E-PLCL copolymers were prepared with 
uniformly dispersed EGCG as shown in FT-IR spectrum (Fig. 1C). Moreover, E-PLCL has 
been shown to have good physicochemical properties such as stable Tm, improved 
hydrophilicity and sustained release of EGCG (Figs. 1B and 2A). The degradation of PLCL 
implicated that a reduction of the polymer chain length by random cleavage of ester bonds, 
without the formation of soluble components, occurred during the experimental time period 
(Figs. 2B and 2C). After the drug elutes from the polymer coating, the residual synthetic 
polymer coating may lead to complications such as an exaggerated inflammatory response 
and neointimal hyperplasia at the implant site. The initial rationale of applying biodegradable 
polymeric coatings to intravascular stents has been to provide a biologically inert carrier and 
to have proper degradation rate. After a stent coating has released the drug it should degrade 
promptly. According to the EGCG release test and the polymer degradation test, PLCL 
degrades minimally during the initial 8 week controlled release phase but might degrade 
gradually after it has finished releasing EGCG. Additionally, these physicochemical 
characteristics and the degradation rate of PLCL can be easily controlled by adjusting the 
ratio of lactide and caprolactone. Compared to other anti-proliferative and/or immune-
suppressive agents utilized in DES, such as paclitaxel, sirolimus and curcumin [27–29], 
EGCG has several advantages. First of all, EGCG is biologically safe. It has been shown to 
have no dermal, acute, reproductive or short-term toxicity, teratogenicity or genotoxicity at 
physiological concentrations [30–32]. The biological safety of other drugs has not been fully 
elucidated yet. Second, it exerts differential dose-dependent migration-inhibitory activity in 
VSMCs vs. vascular endothelial cells. EGCG-mediated inhibition of proliferation and 
migration was found to occur at much higher dose of EGCG in endothelial cells as compared 
to VSMCs [33]. Third, it is effective enough to function at relatively low concentrations. 
EGCG was initially loaded into PLCL at a concentration of 5 wt% (approx. 1100 µmol/film), 
but by 3 days only 110 µM of EGCG had been released (Fig. 2C). The amount is sufficient to 
completely inhibit VSMC migration and invasion. Moreover, our previous report 
demonstrated that EGCG inhibited the proliferation and migration of serum-stimulated 
VSMCs and induced cell cycle arrest by down-modulating nuclear factor-κB [17]. 
The abnormal growth of VSMCs and their excess migration from the tunica media to the 
subendothelial region plays an important role in vascular diseases, including atherosclerosis 
and restenosis after angioplasty or stenting [34]. A number of studies have demonstrated that 
EGCG inhibits the behaviors of VSMCs induced by serum or growth factors [35,36]. In this 
study, it has been demonstrated that EGCG, released from E-PLCL, inhibits the migration 
and invasion of VSMCs (Fig. 3). It has been also shown that the inhibitory effects of EGCG 
are due to its structure with the galloyl group in the 3-position and abundant hydroxyl groups 
[36–38]. There is evidence that this EGCG-mediated inhibition might be ascribed to the 
adsorption of EGCG at specific sites on the cellular membrane or DNA that affects the cell 
proliferation and DNA replication [39,40]. Moreover, a recent study has demonstrated that 
expression of the metastasis-associated 67 kDa laminin receptor (67 LR) might confer EGCG 
responsiveness to cancer cells at physiologically relevant concentrations. This suggests that 
the gallate moiety of EGCG may be critical for 67 LR binding and subsequent activity [41]. 
The observation that nucleic acids extracted from catechin-treated cells were colored, implies 
that both galloyl and catechol groups of EGCG are essential for DNA binding, and both 
groups seemed to hold strands of DNA via their branching structure [42]. These results 
suggest that EGCG may bind to specific receptors onto membranes, be internalized into the 
cytosol and further be translocated into the nucleus. This leads to the interruption of the 
exogenous signals directed to genes responsible for cellular responses including proliferation, 
migration and invasion of VSMCs. 
Biocompatibility of cardiovascular grafts is often evaluated by the deposition of platelets 
and their activation. Platelet adhesion and activation occur during cardiopulmory bypass, 
hemodialysis and implantation of vascular grafts or stents. This may induce early thrombosis 
and late intimal hyperplasia [43]. In this study, incubating PLCL films with PRP from fresh 
whole human blood, resulted in platelet adhesion and activation, as measured by morphology 
change, adhered number and released CD62. Platelet adhesion mainly depends on the types 
and conformation of adsorbed plasma proteins. However, EGCG blending resulted in a 
significant decrease in platelet adhesion and activation onto PLCL as shown by reduced 
number and decreased P-selectin release (Fig. 4). Plasma protein adsorption onto polymers 
strongly depends on their surface characteristics such as hydrophobicity or charge. 
Hydrophobic surfaces have been shown to be more suitable to protein adsorption than 
hydrophilic surfaces [44]. Therefore, enhanced hydrophilicity of PLCL by EGCG addition 
could inhibit the protein adsorption by reducing the interfacial free energy. Proteins attached 
onto E-PLCL might be difficult to undergo conformation change, and thus fewer integrated 
locations of platelet would be exposed and few platelets would be activated [43]. It has been 
reported that EGCG could inhibit platelet aggregation induced by thrombin, collagen, and 
thrombospondin-1. Moreover, EGCG shows an antithrombotic activity that inhibit 
cytoplasmic Ca2+ increase and thromboxane A2 (TXA2) formation through the inhibition of 
arachidonic acid liberation and TXA2 synthase [45–47]. This inhibitory activity seems to be 





These findings provide support to a scenario in which EGCG released from biodegradable 
copolymers plays a key role in the inhibition of VSMC migration and invasion as well as the 
suppression of platelet adhesion and activation. Therefore, it is suggested that EGCG-
releasing polymers can be potentially applied for fabricating an EGCG-eluting vascular stent, 















Figure 1. Physicochemical properties of EGCG-releasing PLCL (E-PLCL) copolymers. A) 
SEM micrographs (× 200) of PLCL and E-PLCL films, B) DSC profiles of PLCL and E-
PLCL (the insert for EGCG) and C) FT-IR spectrum of PLCL and E-PLCL. 
 
Figure 2. EGCG release from E-PLCL and effects of EGCG blending on PLCL degradation. 
A) In vitro release profile of EGCG from E-PLCL film, B) Molecular weight change (in vitro 
degradation) of PLCL and C) Cumulative weight loss of PLCL and E-PLCL films. 
 
Figure 3. Effect of EGCG released from E-PLCL on serum-stimulated VSMC migration and 
invasion. A) Microscopic photographs (× 25) of cells migrated into denuded areas. A small 
scrape was made across a confluent monolayer, and then the process of denuded area closure 
was monitored for up to 72 h in the presence of conditioned media from PLCL or E-PLCL. 
B) Microscopic photographs (× 100) of cells invaded through matrigel and stained with 
toluidene blue. A modified Boyden chamber assay was used with matrigel-coated transwell 
inserts. Cells were incubated in the inner chamber of transwell with conditioned media from 
PLCL or E-PLCL for 72 h. The photographs shown in these figures are representative of 6 
independent experiments, showing similar results.  
 
Figure 4. Effect of EGCG released from E-PLCL on platelet adhesion and activation. A) 
SEM micrographs (× 300 and × 1,000) of adhered platelets. PRP isolated from human whole 
blood was incubated with PLCL and E-PLCL films for 2 h and then observed by SEM. The 
micrographs shown in this figure are representative of 6 independent experiments, showing 
similar results. B) Platelet activation was determined by detecting P-selectin (CD62), as 
described in Materials and Methods. The results are reported as a mean ± SD (n = 6) and 
analyzed by the Bonferroni test. There is significant difference (p < 0.05) between CD62 
activation by incubation with PLCL and E-PLCL. 
 
 Figure 5. Surface morphology and structural integrity of EGCG-eluting stents. A) Optical 
microscopic photos (× 75 and × 200) of an EGCG-eluting stent before and after balloon-
expansion. B) SEM micrographs (× 50 and × 500) of an EGCG-eluting stent after balloon-
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